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Abstract  Stereotactic  radiation  therapy  (SRT)  is  becoming  more  and  more  important  in  the
treatment of  inoperable  patients  with  early  stages  of  pulmonary  carcinomas  (T1-T2  N0M0).  In
certain cases,  evaluation  of  the  response  is  still  problematical  and  it  can  be  difﬁcult  to  differen-
tiate response  from  progression.  The  aim  of  this  paper  is  to  set  out  these  various  changes  and  to
produce a  protocol  for  optimal  monitoring.  By  comparing  our  clinical  experience  with  data  from
the literature,  the  main  visual  aspects  on  a  CT  scan  are  set  out  and  illustrated  for  each  clini-
cal situation:  radiation  pneumonitis,  radiation  ﬁbrosis,  therapeutic  response  and  progression.
The literature  was  reviewed  by  querying  the  main  databases  and  selecting  papers  concerning
pulmonary  SRT  and  post-therapeutic  radiological  appearance.  CT  appearance  induced  by  SRT
differs signiﬁcantly  from  images  after  classic  conformal  radiation  therapy,  both  morphologically
and chronologically.  In  particular,  the  modiﬁcations  induced  by  stereotactic  radiation  therapy
are only  seen  in  a  limited  volume  surrounding  the  volume  treated.  Knowledge  of  the  radiological
criteria necessary  to  differentiate  between  a  therapeutic  response  and  recurrence  is  of  major
importance  in  the  present  context  of  increase  in  use  of  this  technique.
© 2012  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
ContextStereotactic  radiation  therapy  (SRT)  is  used  for  the  management  of  early  stage  pulmonary
carcinomas  in  inoperable  patients  [1—4]. Owing  to  its  great  accuracy,  it  opens  the  way  to
radiation  ablation  treatments  with  very  high  doses  per  fraction  and  a  biological  equivalent
in  the  order  of  110  to  180  Gy  [5].
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A  report  published  by  the  French  National  Author-
ty  for  Health  (Haute  Autorité  en  santé  —HAS)  in  2006
onsidered  the  beneﬁts  expected  from  extracranial  stereo-
actic  radiation  treatment  for  primary  bronchopulmonary
umours  and  slow-growing  pulmonary  metastases  with  a
ontrolled  primary  tumour  as  being  sufﬁcient  [6].  Since
hen,  many  studies,  most  of  them  retrospective  and  with
imited  numbers,  have  been  published  and  have  conﬁrmed
he  usefulness  of  this  type  of  technique  [2—4,7—10].  In
he  years  to  come  therefore,  it  may  well  be  used  more
nd  more  and  possibly  be  considered  for  the  treatment  of
perable  patients  [11], if  the  results  of  prospective  stud-
es  currently  underway  are  convincing  (STARS  and  ROSEL
rials).  Although  the  radiological  appearance  after  frac-
ionated  three-dimensional  conformal  radiation  therapy  has
een  described  in  the  literature  [12], the  CT  changes  follow-
ng  treatment  with  pulmonary  stereotactic  radiation  therapy
iffer  signiﬁcantly  and  have  still  not  been  greatly  described
nd  are  little  known.  Indeed,  the  irradiation  technique,
ose  distribution,  biological  effect  of  high  doses  per  fraction
nd  the  total  time  of  treatment  suggest  that  the  radio-
ogical  results  will  not  be  comparable  with  those  found
fter  conventional  external  beam  radiation  therapy.  Radio-
ogists  and  radiotherapists  consequently  need  to  be  aware
f  the  radiological  appearance  following  such  treatment  in
rder  to  determine  its  efﬁcacy.  The  aim  of  this  review  is
o  describe  and  illustrate  the  early  and  late  CT  characteris-
ics  found  after  SRT,  to  set  out  the  risk  factors  for  toxicity,
nd  to  propose  an  optimal  post-SRT  radiological  monitoring
rotocol.
ethods
e  searched  for  all  the  papers  concerning  SRT,  early  stage
ung  cancer  and  radiological  appearance  after  treatment  in
he  Medline  (Pubmed),  Google  Scholar  and  ScienceDirect
lectronic  databases.  Only  papers  in  French  and  English  pub-
ished  between  1990  and  2011  were  included.  The  keywords
sed  were:  stereotactic  body  radiation  therapy  (SBRT),  lung
ancer,  radiological  ﬁndings,  toxicity,  radiation  pneumoni-
is,  and  radiation  ﬁbrosis.
There  were  two  stages  to  the  process:  ﬁrstly,  we  selected
ll  the  papers  concerning  extracranial  stereotactic  radiation
herapy  applied  to  treatment  of  early  stage  pulmonary  carci-
omas.  Secondly,  we  selected  all  the  papers  devoted  to  the
adiographic  appearance  found  after  SRT  and  other  factors
redicting  toxicity.
Our  centre  has  been  treating  patients  by  stereotac-
ic  radiation  therapy  since  2008  [13]. Three  hundred  and
wenty-four  patients  have  been  treated  in  our  department
or  pulmonary  tumours  with  levels  of  local  control  of  100%
t  6  months  [3],  92%  after  a  year  and  86%  after  2  years
or  the  patients  treated  with  real  time  monitoring  of  the
arget  (results  not  published).  Post-therapeutic  CT  scans
erformed  as  part  of  monitoring  patients  treated  by  robotic
yberKnife® stereotactic  radiation  therapy,  with  real  time
onitoring  of  the  target  without  ﬁducial  marker,  have  pro-
ided  illustrations  of  the  main  eventualities.  All  the  patients
hose  CT  scans  are  presented  were  treated  with  the  proto-
ol  most  generally  used  at  present  (three  sessions  of  20  Gy).
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esults
he  search  found  222  papers  concerning  stereotactic  radi-
tion  therapy  for  the  treatment  of  early  stage  pulmonary
arcinoma.  Of  these,  21  papers  dealt  speciﬁcally  with  the
se  of  imaging  for  evaluating  the  response  and  factors  pre-
icting  toxicity  after  stereotactic  radiation  therapy.
tereotactic radiation therapy for pulmonary
arcinoma
tereotactic  radiation  therapy  is  at  present  playing  an
ncreasing  part  in  the  treatment  of  pulmonary  tumours.The
rinciple  of  stereotactic  radiation  therapy  differs  from  that
f  conformal  radiation  therapy  in  the  very  great  accu-
acy  it  provides.  The  conformality  of  the  therapy  is  greatly
mproved  by  multiplying  the  number  of  treatment  beams
up  to  150  in  certain  treatment  plans)  which  are  often  non-
oplanar  and  non-isocentric  [14]. It  is  possible  to  increase
he  dose  per  fraction,  the  total  dose,  and  thus  the  biological
quivalent  dose,  allowing  ablative  doses  to  be  reached  and
ccess  to  the  area  of  extracranial  radiosurgery.  This  treat-
ent,  for  inoperable  patients  with  pulmonary  carcinoma,  is
eserved  for  early  stages,  T1  or  T2,  of  less  than  6  cm,  with
o  lymph  node  or  distant  metastases.
ifferences from conformal EBRT
or  conventional  radiation  therapy,  the  lung  injuries  induced
re  usually  described  as  early  or  late  reactions  [13,15].
Early  reactions  occur  between  1  and  6  months  after  treat-
ent.  Fibrosis  appears  on  pulmonary  parenchyma  having
ad  radiation  pneumonitis  and  becomes  apparent  between
2  and  24  months  after  the  radiotherapy.  Most  of  these
ccurrences  are  asymptomatic  and  do  not  require  speciﬁc
reatment.  CT  modiﬁcations  affect  the  ﬁeld  of  treatment
nd  do  not  keep  to  anatomical  limits.  Condensations,  ground
lass  opacities  and  an  inﬁltrate  in  the  treated  area,  with  or
ithout  disappearance  of  the  vascular  or  bronchial  contours,
re  characteristic  of  the  initial  phase,  in  which  nodules  or
ocal  condensations  may  also  appear.  Pleural  effusion  may
ometimes  be  found.  These  aspects  can  gradually  regress  or
ead  to  pulmonary  ﬁbrosis  in  the  severest  cases.
Pulmonary  ﬁbrosis  appears  as  a  well-deﬁned  area  of  loss
f  volume,  linear  scarring,  septal  thickening,  opacity  and
ronchiectasis  producing  a  picture  of  interstitial  pneumonia.
ediastinal  deviation  may  also  be  found.  The  characteris-
ic  SRT  dose  distribution  is  radically  different  from  that  of
reatment  using  standard  conformal  radiation  therapy  [16].
onsequently,  lung  injuries  induced  by  SRT  are  not  presented
n  the  same  way:  the  linear  shape  of  lung  injuries  caused
y  conformal  radiation  therapy,  clearly  delineated  between
he  irradiated  and  non-irradiated  tissue,  is  not  found  here.
n  SRT,  the  low  dose  regions  are  larger  and  irregular,  since
here  are  more  treatment  beams  and  more  angles.  In  con-
rast,  the  high  dose  area  is  uniform  and  smaller  in  size.  The
hape  of  SRT-induced  lesions  thus  more  precisely  matches
he  initial  PTV  and  is  not  linear.  A  spherical  shape  is  often
ound  which  is  perhaps  explained  by  the  great  conformality
nd  homogeneity  of  the  dose.  Secondly,  the  chronology  of
he  appearance  of  abnormalities  is  different:  most  changes
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appear  less  than  3  months  after  treatment.  This  latency
period  is  not  found  with  conformal  radiation  therapy  since
the  majority  of  modiﬁcations  occur  in  the  ﬁrst  weeks  after
treatment  [17,18].  This  difference  may  be  explained  by  the
radiobiology  of  high  doses  per  fraction  [5,19,20].
Radiofrequency as treatment of early stage
bronchial carcinoma
Radiofrequency  ablation  (RFA)  is  a  minimally  invasive  tech-
nique  initially  used  as  a  palliative  treatment  for  pulmonary
carcinomas  which  has  gradually  become  a  curative  option
for  inoperable  patients,  in  the  same  way  as  stereotactic
radiation  therapy.  Studies  report  levels  of  local  control  of
between  57%  and  100%,  depending  on  the  stage  treated
[21—26].  This  technique  has  the  advantages  of  being  able
to  be  offered  to  inoperable  patients  and  of  being  per-
formed  in  one  session.  It  can  also  treat  several  pulmonary
lesions.  Its  drawbacks  are  related  to  the  transthoracic  punc-
ture  needed  for  the  procedure,  particularly  haemorrhage  or
pneumothorax.  However,  these  complications  are  not  com-
mon,  ranging  between  10%  and  34%  [22,24]  if  patients  are
correctly  selected.  When  patients  are  considered  to  be  too
greatly  at  risk,  particularly  for  the  puncture,  a  stereotactic
radiation  technique  with  non-invasive  monitoring  of  the  tar-
get  can  be  suggested.  Finally,  RFA  carries  no  risk  of  radiation
pneumonitis  or  pulmonary  ﬁbrosis,  which  can  sometimes  be
encountered  after  stereotactic  radiation  therapy.
Main radiological visual aspects after
stereotactic radiation therapy
The  radiologist  who  has  to  assess  the  changes  in  a  patient’s
pulmonary  carcinoma  treated  by  SRT  faces  many  difﬁculties.
Differentiating  progression  of  the  disease  from  a  response
can  often  prove  difﬁcult  given  the  speciﬁc  radiological  char-
acteristics  explained  above.  However,  knowledge  of  some
clearly  described  radiological  signs  will  help  answer  the
majority  of  questions.  We  will  now  ﬁrst  set  out  the  signs
related  to  toxicity  of  the  treatment,  then  those  connected
•
Figure 1. A 84-year-old female patient treated for a right upper lobe
treatment showing radiation pneumonitis extending to the area which h
with persistence of an air bronchogram.tion  therapy  257
ith  progression  of  the  disease,  and  ﬁnally  the  signs  sug-
esting  a  therapeutic  response.
adiological signs related to toxicity of the
reatment
arly  toxicity
he  principle  of  stereotaxy  consists  of  increasing  the  num-
er  of  incidences  of  photon  beams  converging  on  the  target,
hus  creating  a  strong  dose  gradient  between  the  adjacent
rgans  at  risk  and  the  tumour  to  be  treated.  This  particu-
ar  feature,  which  distinguishes  it  from  standard  conformal
adiation  therapy,  creates  unique  radiographic  changes.
The  changes  induced  by  SRT  have  been  classed  into  ﬁve
ategories  [27,28]:
diffuse  condensation  (Fig.  1):  diffuse,  uniform  increase
in  the  attenuation  of  the  pulmonary  parenchyma  which
masks  the  vessels  and  the  bronchial  walls  and  totally  ﬁlls
the  ﬁeld  of  irradiation.  An  air  bronchogram  may  be  seen
in  the  treated  area;
diffuse  ground  glass  opacity  (Fig.  2):  increase  in  the  den-
sity  of  the  parenchyma,  this  time  retaining  the  vascular
and  bronchial  contours  present  in  the  treated  area;
patchy  heterogeneous  condensation  with  ground  glass
opacity:  heterogeneous  mosaic  areas  of  increased  density
which  no  longer  totally  ﬁlls  the  area  treated;
mosaic  of  ground  glass  opacity:  patchy  areas  of  increased
attenuation  and  normal  tissue  density  found  around  the
tumour,  not  totally  ﬁlling  the  area  treated;
no  reaction:  no  increase  in  the  density  of  the  parenchyma
in  the  area  treated.
ate  toxicity
he  appearance  of  pulmonary  ﬁbrosis  induced  by  SRT  has
een  classiﬁed  into  four  categories  [27,29]:
modiﬁed  conventional  images  (Fig.  3):  condensation,  loss
of  volume,  bronchiectasis  similar  but  less  extensive  than
in  conventional  conformal  radiation  therapy;
mass  type  image  (Fig.  4):  limited  focal  condensation
around  the  tumour;
 lesion: a: CT scan before treatment; b: CT scan 4 months after
ad received the maximum dose, shown by irregular condensation
258  J.-E.  Bibault  et  al.
F lobe
t
•
•
t
m
D
r
T
c
i
v
u
R
i
n
u
m
g
a
r
p
4
e
r
5
t
i
c
n
F
tigure 2. A 74-year-old male patient, treated for a left upper 
reatment with poorly demarcated ground glass appearance.
scarring  image  (Fig.  5):  linear  opacity  located  in  the
region  of  the  tumour  associated  with  loss  of  pulmonary
volume;
no  radiological  interpretation:  no  increase  in  density  in
the  ﬁeld  of  treatment.
In a  study  by  Trovo  et  al.  [16], 74  to  76%  of  the  patients
reated  had  images  compatible  with  pulmonary  ﬁbrosis.  In
ost  cases,  these  images  stabilised  after  12  months.
ifferential diagnosis between recurrence and
adiological changes induced by SRT
he  main  signs  of  recurrence  described  in  three-dimensional
onformal  radiation  therapy  —– ﬁlling  of  the  bronchiectases
nduced  by  the  radiotherapy  and  the  appearance  of  a  con-
exity  at  the  limits  of  the  mass  [30,31]  —– cannot  always  be
sed  when  an  SRT  has  been  performed  [32,33].  Similarly,  the
ECIST  criteria  are  sometimes  no  longer  usable  because  an
ncrease  in  condensation  of  the  pulmonary  parenchyma  is
b
t
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igure 3. A 83-year-old male patient, treated for a right upper lobe
reatment, showing widespread radiation ﬁbrosis which could be interpr lesion: a: CT scan before treatment; b: CT scan 3 months after
ot  always  correlated  with  progression  when  SRT  has  been
ndertaken.  The  signs  need  therefore  to  be  described  which
ake  it  possible  to  differentiate  between  continued  pro-
ression  and  expected  recurrence  of  toxicity  due  to  the  SRT.
Two  studies  have  taken  an  interest  in  changes  in  images
fter  SRT  and  in  the  signs  which  ought  to  indicate  recur-
ence.  Matsuo  et  al.  followed  40  pulmonary  tumours  (30
rimary  and  10  metastases)  treated  by  SRT  [33]. For  the
3%  patients  in  partial  response,  the  median  minimal  diam-
ter  was  found  after  8  months  of  treatment.  The  complete
esponse  rate  (disappearance  of  the  tumour)  was  20%.  Up  to
7%  of  the  patients  presented  radiation  pneumonitis  reac-
ions  which  were  impossible  to  evaluate.  Only  the  increase
n  condensation  after  12  months  was  found  to  be  a  statisti-
ally  signiﬁcant  factor  for  recurrence  (P  =  0.001).  The  other,
on-signiﬁcant  factors  explored  were  the  disappearance  of
ronchiectasis  in  the  volume  treated,  the  degree  of  radia-
ion  pneumonitis,  modiﬁcations  before  12  months  and  dose
onformality.  However,  a  second  study  by  Kato  et  al.  [34]
n  27  patients  treated  by  SRT  for  early  stage  pulmonary
 lesion: a: CT scan before treatment; b: CT scan 15 months after
eted as recurrence.
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Figure 4. A 68-year-old male patient, treated for a right lower lobe lesion: a: CT scan before treatment; b: CT scan 6 months after
treatment: mass type consolidation, with persistence of an air bronchogram.
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sFigure 5. A 74-year-old male patient, treated for a right lower 
treatment with the appearance of scarring in the treatment area.
carcinoma  found  ﬁve  recurrences  and  showed  the  impor-
tance  of  the  disappearance  of  bronchiectasis  as  a  sign  of
recurrence.  Of  the  patients  who  developed  recurrence,
three  had  had  an  air  bronchogram  following  the  SRT  all  of
which  disappeared  (100%).  In  addition,  the  patients  with
recurrence  all  presented  pleural  effusion  and  an  increase
in  diameter  of  the  condensation  12  months  or  more  after
the  SRT.
The  main  signs  which  should  therefore  suggest  recurrence
rather  than  radiation  pneumonitis  are:
• location:  continuity  with  the  treated  tumour  lesion;
• distribution:  modiﬁcation  of  the  contours  of  the  ﬁbrosis;
• radiological  signs:
◦ disappearance  of  bronchiectasis  initially  found,
◦ appearance  of  pleural  effusion;
• chronology:
◦ modiﬁcations  are  possible  between  6  and  9  months,
◦ after  12  months,  an  increase  in  size  or  a  modiﬁcation
of  the  contours  should  no  longer  be  found.
w
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ptumour: a: CT scan before treatment; b: CT scan 6 months after
elationship between CT scan modiﬁcations
nd pulmonary emphysema
tereotactic  radiation  therapy  for  pulmonary  lesions  is  cur-
ently  indicated  for  inoperable  patients.  The  majority  of
hese  patients  are  elderly  [35,36]  or  have  considerable
ulmonary  comorbidities  such  as  an  advanced  stage  of
mphysema.  It  is  therefore  important  to  know  the  type
f  parenchymal  reactions  induced  by  SRT  in  this  type  of
atient  so  as  to  be  able  to  determine  the  response  and
elect  patients  who  can  beneﬁt  from  the  treatment  without
eeding  to  anticipate  increased  toxicity.  The  role  of  pul-
onary  emphysema  in  the  reaction  of  lung  tissue  to  SRT
as  been  explored  by  Kimura  et  al.  [28]. In  their  study,
8  of  the  47  patients  (52  lesions)  treated  had  emphy-
ema  (almost  exclusively  men,  n  =  17).  Expiratory  volume
as  lower  in  patients  with  emphysema  (FEV  greater  than
0%  in  19  patients  without  emphysema  but  in  only  six
atients  with  emphysema).  The  percentage  of  patients  with
260  J.-E.  Bibault  et  al.
Figure 6. A 63-year-old female patient with a history of right upper and middle lobectomy in 2005 for a hilar neuro-endocrine
tumour and adjuvant radiotherapy for capsular rupture of a lymph node in station 7r. A CT scan in July 2008 found a PET ﬁxing
right lower lobe node. Treated by CyberKnife® (3 × 20 Gy) in November 2008: a: CT scan before treatment; b: treatment dosimetry
produced by CyberKnife® — coronal slice; c: treatment dosimetry produced by CyberKnife® — sagittal slice; d: CT scan 6 months after
treatment — transverse slice with dosimetry; e: CT scan 6 months after treatment — sagittal slice with dosimetry: the area of peritumoral
radiation pneumonitis corresponds to the crossing of the treatment beams.
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pulmonary stereotactic radiation therapymphysema  was  lower  among  those  showing  diffuse
ondensation  (P  =  0.0108)  or  modiﬁed  conventional  images
P  =  0.0288).  In  addition,  the  patients  with  emphysema  pre-
ented  more  scar  type  reactions  (P  =  0.00038)  or  showed  no
ncrease  in  density  (P  =  0.00044).
S
iodiﬁcation of respiratory functions aftertereotactic  radiation  therapy  does  not  seem  to  have  any
mpact  on  the  pulmonary  functions  of  patients  treated.
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Stephans  et  al.  have  published  a  study  on  134  patients  eval-
uating  the  modiﬁcations  to  respiratory  function  tests  after
pulmonary  stereotactic  therapy  [37]. The  forced  expiratory
volume  in  1  second  (FEV1)  decreased  non-signiﬁcantly  by
0.05  L  (from  —0.98  to  +1.29,  P  =  0.22).  The  mean  diffusion
capacity  of  the  lungs  for  CO  (DLCO)  similarly  decreased
non-signiﬁcantly  by  2.59%  (from  —37%  to  +33%,  P  =  0.27).
There  was  no  signiﬁcant  difference  in  variation  of  the  FEV1
between  patients  treated  for  central  or  peripheral  tumours
(P  =  0.55).
Proposals for a monitoring protocol
Radiation  pneumonitis  reactions  are  common  at  3  and  6
months  and  even  if,  in  the  majority  of  cases,  they  have  no
clinical  consequences,  they  make  evaluation  of  the  response
difﬁcult.  These  reactions  resolve  spontaneously  and  often
require  no  treatment.  Corticosteroids  are  however  some-
times  necessary  for  the  most  serious  cases.  Up  to  10%  of
patients  present  radiation  pneumonitis  after  SRT  [38], so
that  it  is  therefore  essential  to  monitor  these  patients  early
on  and  in  the  long  term,  ﬁrstly  to  detect  the  most  severe
cases  needing  treatment  and  secondly  in  order  to  distinguish
between  a  response,  radiation  pneumonitis  and  progression.
At  present,  there  are  two  recommendations  which  can
be  applied  to  patients  treated  by  SRT.  The  ﬁrst,  published
by  the  American  College  of  Chest  Physicians  (ACCP)  in  2007
[39], concerns  monitoring  patients  with  non-small  cell  lung
cancer  undergoing  curative  treatment.  For  this  population,
the  ACCP  recommends  monitoring  for  complications  due  to
the  treatment  for  3  to  6  months  and  CT  or  chest  X-ray
screening  for  recurrence  every  6  months  for  2  years,  then
annually.  The  European  Society  for  Medical  Oncology  (ESMO)
also  published  recommendations  in  2009  [40], pointing  out
that  monitoring  treated  patients  is  still  controversial  and
proposing  an  imaging  examination  every  3  to  6  months  for
2  years,  then  every  6  to  12  months  afterwards.  This  follow-
up  protocol  could  be  adapted  for  patients  treated  by  SRT.
Appropriate  close  monitoring  could  consist  of  a  thoracic-
abdominal-pelvic  CT  scan  at  1,  3,  6,  9  and  12  months,  then
every  6  months.  Several  centres  also  use  FDG-PET  to  detect
recurrence,  although  to  date  the  level  of  evidence  is  not
sufﬁcient  for  its  use  in  monitoring.  For  this  approach  to  be
considered  valid,  an  FDG-PET  would  have  to  be  performed
before  the  treatment,  then  at  6  months  and  then  every  6
months,  alternating  with  a  CT  scan  for  2  years,  the  annually
after  that.  Performing  an  FDG-PET  before  6  months  could
ﬁnd  abnormal  FDG  uptake  in  the  area  treated  without  it
being  possible  to  decide  between  progression  and  radiation
pneumonitis.  It  could  also  be  interesting  to  merge  the  re-
evaluation  CT  scan  and  the  dosimetry  of  the  treatment  given
(Fig.  6)  to  determine  whether  the  areas  affected  by  the
attenuation  modiﬁcations  correspond  to  the  ﬁeld  treated.
Conclusion
The  radiological  changes  induced  by  pulmonary  stereotactic
radiation  therapy  are  speciﬁc  to  this  technique  and  dif-
fer  from  the  visual  aspects  known  for  conformal  radiation
therapy,  in  terms  of  topography  and  chronology.  Evalua-
tion  of  the  response  is  therefore  based  on  criteria  which
[tion  therapy  261
adiologists  and  radiotherapists  need  to  know.  Dose  distri-
ution  is  an  essential  element  which  helps  understand  the
iological  phenomena  induced  by  the  treatment  and  should
herefore  be  used  to  interpret  the  results.
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